PAPADOPOULOS DIMITRIOS

EDUCATION & ACADEMIC DEGREES

• Associate Professor of Neurology, European University of Cyprus- ( 2021- today)
• Scientific Associate of the Hellenic Pasteur Institute (2016- today)
• Scientific Associate of the Laboratory of Histology-Embryology of the University of Athens (2014- today)
• Fellow of the European board of Neurology (2012)
• Specialization in neuroimmunology and multiple sclerosis, Imperial College London, London, UK; 2006-2008
• PhD in neuroscience- Imperial College London, University of London- 2003
• Diploma of Imperial College (Neuropathology)- Imperial College London, London, UK- 2004
• Bachelor of Medicine National and Kapodistrian University of Athens- 1998
• Graduated from Anavryta School Junior-Senior High School- 1991

WORK EXPERIENCE

• Director of the Metropolitan General 3rd Neurology Clinic - 2023 to date
• Director of the Neurology Department - Athens Medical Center - Clinic of Palaio Faliro (2012- 2022)
• Director of Multiple Sclerosis Practice - Athens Medical Center - Clinic of Palaio Faliro (2012-2023)
• Clinical research Fellow (lecturer level), Department of Cellular and Molecular Neuroscience and MS center, Imperial College London, London, UK (2006-2008)
• Clinical researcher - Multiple Sclerosis Trials Consortium (MSTC). Clinical Neurosciences, Charing Cross Hospital, Imperial College London, UK (2006-2008)
• Resident in Neurology, Neurology Clinic, "Evangelismos Hospital", Athens
• Resident in Psychiatry, State Hospital of Leros
• Resident in Pathology, Naval Hospital of Athens
• Resident in Pathology, Naval Hospital of Crete
• Ensign Assistant Medical Officer, Navy (2003-2004)
• Research Fellow – Department of Neuroinflammation & repair, Charing Cross Hospital, Imperial College London, University of London, UK (1999-2003). PhD thesis: "Axonal damage and loss in the MOG-EAE model of EAE and MS" under the supervision of Professor Richard Reynolds. with a three-year fellowship from the North Atlantic Treaty Organization (NATO)
• Field service - Vasiliki Health Center - General Hospital of Lefkada (1998-1999)

MEMBER OF ASSOCIATIONS, AUTHORING TEAM OF JOURNALS

• Member of the American Academy of Neurology - Neuroimmunology Branch
• Member of the Hellenic Neurological Society
• General Medical Council-UK (GMC) specialist register
• Medical Association of Athens
• Ad hoc reviewer in scientific journals: Ageing Cell, Pharmaceuticals, Journal of Neuroendocrinology, Journal of Neuroscience, Molecules, Neuropsychiatric Disease and Treatment, Pharmaceutics, Nutrients, Cellular and Molecular Neurobiology, International journal of Molecular Sciences. CNS Drugs. Immunology Letters, Clinical Drug Investigation, BMC neurology
• Research Project Reviewer for the Alzheimer's Society, UK (2019)
• Research Project Reviewer for the Australia MS Society (2008)

RESEARCH PROGRAMS

• Funding for a research project entitled: “Is cellular senescence responsible for disability progression in progressive multiple sclerosis?”. 2018-2019. Organization: Multiple Sclerosis Society of Great Britain and Northern Ireland
• Funding for a research project entitled: “The role of cellular senescence and aging in disability progression in multiple sclerosis” 2017-2019. Organization: Multiple Sclerosis Trials Collaboration (MSTC), UK

Clinical studies

• CHRONOS study (principal investigator). Non-interventional, multicentric observational study to evaluate the efficacy and patient-reported outcomes of ofatumumab in patients with relapsing-remitting multiple sclerosis, Status: in progress
• FAMILY study (principal investigator). A phase 4 non-interventional observational observational study to investigate the effect of fabridine on cognitive function, fatigue, depression and quality of life in multiple sclerosis. Sponsored by the company GENESIS PHARMA. Status: completed.
• CLADCROSS study (principal investigator). A prospective multicenter observational study of quality of life and safety of cladrstusivine in multiple sclerosis. Sponsored by Merck. Status: completed.
• LemQoL/OBS14449 Clinical Trial study (principal investigator). Prospective multicenter observational study of safety and quality of life in patients with relapsing multiple sclerosis treated with alemtuzumab. Sponsored by Sanofi. Status: completed.
• RECORD Clinical Study (principal investigator). Non-interventional observational study of the effect of dimethyl fumarate on focal load and cervical cord atrophy in multiple sclerosis. Sponsored by the company Genesis Pharma. Status: completed.
• FTY720D2316 Study: (Investigator). An observational study of the safety and tolerability of fingolimod in patients with relapsing multiple sclerosis. Sponsored by NOVARTIS. Status: completed.
• TRANSFORMS Clinical Trial: (Investigator). A double-blind randomized multicenter phase 3 study comparing the efficacy and safety of 0.5 mg and 1.25 mg Fingolimod (FTY720) versus Interferon ß-1a in patients with relapsing multiple sclerosis. Sponsored by NOVARTIS. Status: completed.

HONORARY DISTINCTIONS

• North Atlantic Treaty Organization (NATO) Doctoral Fellow (1999-2003)
• Travel scholarship for a lecture at the 5th ECTRIMS-ACTRIMS combined conference on 19-22 October 2011, Amsterdam.
• Travel scholarship for oral presentation at the 23rd ECTRIMS, 11-14 October 2007, Prague.
• First prize for scientific paper at the symposium of the School of Health Sciences, Imperial College London, 10-07-2001, Hammersmith Hospital, Imperial College, London, UK.
• First prize scientific paper award at the first annual neurodegenerative disorders symposium of Merck Sharp & Dohm and GlaxoSmithKline pharmaceuticals on 25-09-2001, Harlow, Essex, UK.

LECTURES AT POINTS-AWARDED CONFERENCES AND ACADEMIC CENTRES

Abroad

1. «Accelerated cellular senescence in a model of multiple sclerosis» In session: “MS Novel Therapeutics and Animal Models”. 69th Annual Meeting of the American Academy of Neurology, 28 Απριλίου 2017, Bοστώνη, ΗΠΑ.
2. «TNFR2-expressing non-haematopoetic cells modulate the immunosuppressive activity of FoxP3+ regulatory T cells in MOG-EAE». Parallel session 11, “Cell-based therapies” Joint American and European conference on the treatment and research in multiple sclerosis (ECTRIMS-ACTRIMS), 21 Oκτωβρίου, 2011, Άμστερνταμ.
3. “TNFR2 and Tregs in a model of MS”.1st Annual World Congress of Immunodiseases and Therapy. 15-17 Μαΐου, 2010, Πεκίνο, Κίνα.
4. “Neurodegenerative changes in MS and EAE”. Προσκεκλημένος ομιλητής στο Queen Mary’s University of London Neuroscience Centre (Prof Gavin Giovannoni). 9 Φεβρουαρίου, 2007, London, UK.
5. “Axonal loss is the pathological correlate of permanent disability in the MOG-induced model of MS in the DA rat” στο 103ο Franco-British Neuropathological Society meeting, 18-20 Δεκεμβρίου 2002, Southampton, UK.
6. “Axonal damage in MOG-induced EAE in the rat” στο «EAE: Immune Mechanisms workshop». 6th International Congress of the International Society of Neuroimmunology, 4 Σεπτεμβρίου 2001, Εδιμβούργο, Σκωτία.

Greece

1. "Multiple sclerosis-related headache". Annual conference of the Hellenic Headache Society. March 14, 2024, Volos.
2. “Multiple sclerosis. de-escalation and bridge treatments" Achaean Neurology Days, September 14, 2024, Patras.
3. Will the presence of the central vein sign lead to a change in the diagnostic criteria of the disease? 10th Transclinical Symposium on Multiple Sclerosis. May 17, 2024, Polygyros, Halkidiki.
4. ''Treatment of a patient with MS and other coexisting autoimmune disease'' 17th Symposium of Neurology of the Academy of Neurosciences, May 6, 2023, Ioannina, Greece.
5. Newer highly effective therapies in high-activity Multiple Sclerosis, 10th Educational Seminar, Achaean Neurology Days. September 16, 2023.
6. Focusing on the optic nerve: what is its new role in the diagnosis and monitoring of the disease? 9th Transclinical Symposium on Multiple Sclerosis. September 30, 2023, Polygyros, Chalkidiki.
7. "Autoimmune encephalitis for the non-specialist" 6th Systemic Lupus Erythematosus School, December 2, 2023. National Research Foundation, Athens.
8. "Tolerance to treatments: how it is evaluated and what it determines" Annual conference of the Hellenic Headache Society. March 18, 2022, Arachova.
9. "Suboptimal response to treatment: definition and prognosis" 8th Interclinical Symposium on Multiple Sclerosis. May 14, 2022, Chalkikidi.
10. "Inflammatory diseases of the CNS". 15th Symposium on Neurology of the Academy of Neurosciences, October 2, 2021, Ioannina.
11. "Cancer and Multiple Sclerosis Therapy". 7th Interclinical Symposium on Multiple Sclerosis. May 22, 2021, Thessaloniki.
12. "Disorders in the immunobiological background in multiple sclerosis" 6th Panhellenic Conference "Newest developments in neurology and related fields", March 7, 2020, Thessaloniki.
13. "Migraine: the most common cause of disability in young adults", " The Palaio Faliro Medical Center Continuing Medical Education Points-Awarded Programme 2019-2020" , January 22, 2020, Athens.
14. "When and how to start treatment in multiple sclerosis" 14th Academy of Neurosciences Neurology Symposium, October 22, 2020, online.
15. "Off-label administration of B cell therapies" 6th Transclinical Symposium on Multiple Sclerosis, October 19, 2019, Athens.
16. "Aging of the immune system: implications for efficacy and safety in multiple sclerosis therapy" 6th Transclinical Symposium on Multiple Sclerosis, October 19, 2019, Athens.
17. "Risk management in multiple sclerosis" 13th Summer Symposium on Neurology of the Hellenic Academy of Neurosciences, April 20, 2019, Ioannina.
18. "Neurocognitive disorder: developments in diagnosis and treatment", The Palaio Faliro Medical Center Continuing Medical Education Points-Awarded Programme 2019-2020, March 6, 2019, Athens.
19. "Escalation of immunomodulatory treatment: the role of neurofilaments" 5th Transclinical Symposium on Multiple Sclerosis, November 9-11, 2018, Thessaloniki.
20. "Management of patients with high activity disease in clinical practice" 5th Interclinical Symposium on Multiple Sclerosis, November 9-11, 2018, Thessaloniki.
21. "Basic concepts of neuroimmunology: The role of the immune system in the genesis of autoimmune neurological diseases" Clinical Neurology Topics, September 20-23, 2018, Nafplio.
22. "Neurofilaments as a biomarker in the treatment of multiple sclerosis", 6th workshop on multiple sclerosis, Naval Hospital of Athens, June 29, 2018, Athens.
23. "Studies with direct comparison of two drugs - critical review" 12th Summer Symposium on Neurology of the Hellenic Academy of Neurosciences, May 12, 2018, Rhodes.
24. "Outside-in pathology of MS". 3rd Military Hospitals Neurology Symposium. April 12-14, 2018, Spetses.
25. "Immunology basics for clinicians, starting from A".at the 3rd Military Hospital Neurology Symposium. April 12-14, 2018, Spetses.
26. "Recent immunological data on the pathogenesis of multiple sclerosis: do they affect treatment response?" 3rf Annual Educational Seminar of the Department of Neurology of the Athens Medical Center, March 18, 2018, Aegina.
27. "Inflammatory/ Demyelinating diseases of the CNS: From pathogenesis to new treatments" 1st School of Basic Immunology for clinicians, Pancretan Health Association and University Clinic of Rheumatology of Heraklion, October 6-8, 2017, Heraklion, Crete.
28. "Preclinical studies in multiple sclerosis at the 69th AAN" at the5th Scientific Forum" From Boston to Syros": Review from the AAN meeting 2017 on multiple sclerosis and headaches" Organized by the Neurology Clinic of the Naval Hospital of Athens and the Hellenic Academy of Neurosciences, June 2-4, 2017, Ermoupolis, Syros.
29. "B lymphocytes" at the 5th Scientific Forum" From Boston to Syros": Review from the AAN meeting 2017 on multiple sclerosis and headaches" Organized by the Neurology Clinic of the Naval Hospital of Athens and the Hellenic Academy of Neurosciences, June 2-4, 2017, Ermoupolis, Syros.
30. "Prognostic indicators of response to treatment" 11th Summer Symposium on Neurology of the Hellenic Society of Neurosciences. May 18-21, 2017, Corfu.
31. "Pathogenesis mechanisms in multiple sclerosis: newer data": Cognitive disorders of neurological diseases - from symptom to disease" Scientific conference under the auspices of the Society for the Promotion of Integrated Mental Health Services, March 17-19, 2017, Vytina Arcadia.
32. "Is the progression of disability the result of inflammation or neurodegeneration? Neurodegeneration" Two-Day Military Hospitals Neurology Workshop, March 6, 2017, Athens.
33. "PP-MS: where are we going?" Neurology Evenings of the 1st Neurology Clinic of the University of Athens, Aeginitio Hospital, February 7, 2017, Athens.
34. "The role of T and B lymphocytes" 4th Conference on New Developments in Neurology and Related Fields, 20-22 October, 2016, Thessaloniki.
35. "Pharmacological treatment of cognitive dysfunction in multiple sclerosis", at the scientific event of the 1st Neurology Clinic of the University of Athens on "Cognitive disorders in MS", June 17-20, 2016, Poros.
36. "Pathogenesis mechanisms in multiple sclerosis: newest data" at the 2nd Panhellenic Conference of the Neurology Department of the Athens Medical Center, June 4, 2016, Athens.
37. "The role of B lymphocytes in MS". Invited speaker at the conference "From Vancouver to Syros: Review of the American Academy of Neurology Meeting 2016 on multiple sclerosis". Under the auspices of the 1st University Neurology Department of the University of Athens, May 20-21, 2016, Ermoupoli, Syros.
38. "Preclinical studies in MS". Invited speaker at the conference "From Vancouver to Syros: Review of the American Academy of Neurology Meeting 2016 on multiple sclerosis". Under the auspices of the 1st University Neurology Department of the University of Athens, May 20-21, 2016, Ermoupoli, Syros.
39. "ADEM & MS: is there a way to distinguish early a monophasic ADEM from An ADEM that is going to progress to MS and thus needs to be treated? - Yes” Two-Day Military Hospitals Neurology Workshop, April 2, 2016, Athens.
40. "Immunological mechanisms in multiple sclerosis" Residents' Course 401 Athens General Military Hospital, January 19, 2016, Athens.
41. “Developments in multiple sclerosis therapeutics", The Palaio Faliro Medical Center Continuing Medical Education Points-Awarded Programme 2015-2016, December 16, 2015, Athens.
42. "Inflammation and neurodegeneration in relapse" 3rd Panhellenic Conference of the Hellenic Society of Neuroimmunology, November 19-22, 2015, Athens.
43. "Immunological mechanisms of multiple sclerosis". Invited speaker at the conference "From Washington to Porto Heli: Review of the American Academy of Neurology Meeting 2015 on multiple sclerosis". Organized by the Neurology Clinic of the Naval Hospital of Athens and the Hellenic Academy of Neurosciences, May 29, 2015, Porto Heli.
44. "Future therapies in MS". Invited speaker at the conference "From Washington to Porto Heli: Review of the American Academy of Neurology Meeting 2015 on multiple sclerosis". Organized by the Neurology Clinic of the Naval Hospital of Athens and the Hellenic Academy of Neurosciences, May 29, 2015, Porto Heli.
45. "Lessons from the immunopathology of multiple sclerosis: are we shooting for the right target?" 11th Summer Symposium on Neurology of the Hellenic Society of Neurosciences. May 23, 2015, Rhodes.
46. "Pathophysiology of cognitive dysfunction in multiple sclerosis" 9th Panhellenic Interdisciplinary Conference on Alzheimer's Disease and Congenital Disorders and 1st Mediterranean Conference on Neurodegenerative Diseases, May 16, 2015, Thessaloniki.
47. "Basic Research Studies on MS" at the 2nd Scientific Forum" From Philadelphia to Porto Heli": Review from the AAN meeting 2014 on multiple sclerosis" Organized by the Neurology Clinic of the Naval Hospital of Athens and the Hellenic Academy of Neurosciences, June 13-15, 2014, Porto Heli.
48. "The immunological mystery of multiple sclerosis: clinical approach of the neuroimmunologist" 1st points-awarded seminar on neurological diseases of the Medical Center Group, January 17-18, 2014, Athens.
49. "Strokes in clinical practice" Points-awarded continuing medical education program of Palaio Faliro Medical Center 2013-2014, September 25, 2013, Athens.
50. "Neuroimmunology" Invited speaker at the conference "From San Diego to Tzia: Review of the American Academy of Neurology Meeting 2013 on multiple sclerosis". Organized by the Neurology Clinic of the Naval Hospital of Athens and the Hellenic Academy of Neurosciences, May 17-19, 2013, Kea.
51. "Acute disseminated encephalomyelitis (ADEM)". Invited speaker at the conference "From San Diego to Tzia: Review of the American Academy of Neurology Meeting 2013 on multiple sclerosis". Organized by the Neurology Clinic of the Naval Hospital of Athens and the Hellenic Academy of Neurosciences, May 17-19, 2013, Kea.
52. "Acute disseminated encephalomyelitis (ADEM)" Invited speaker at the postgraduate course of the neurology clinic of the Naval Hospital of Athens. October 30, 2012, Athens.
53. "Immune shock treatments". Postgraduate course of the neurology clinic of the Naval Hospital of Athens. September 30, 2012, Athens.
54. “Multiple sclerosis. From demyelination to neurodegeneration". Invited speaker at the postgraduate seminars of the Department of Histology & Embryology of the Medical School of Athens, September 28, 2012.
55. "Progressive multifocal leukoencephalopathy associated with natalizumab administration". Invited speaker in the cycle of seminars of the neurology clinic of the Evangelismos General Hospital of Athens. June 19, 2012, Evangelismos General Hospital, Athens.
56. “Multiple sclerosis. New therapeutic approaches and optic neuritis". Invited speaker in the cycle of seminars of the Athens Vision ophthalmological center. December 16, 2011, Athens.
57. "Summary of immunological mechanisms in multiple sclerosis" Invited speaker at the postgraduate course of the neurology clinic of the Naval Hospital of Athens. November 30, 2010, Naval Hospital of Athens.
58. “Vaccines in the treatment of MS”. Invited speaker at the postgraduate course of the neurology clinic of the N.N.A. December 9, 2008, Athens.

PUBLICATIONS

Publications in peer-reviewed journal

(Google Scholar >1900 citations)

• Papadopoulos D, Magliozzi R, Bandiera S, Cimignolo I, Barusolo E, Probert L, Gorgoulis V, Reynolds R, Nicholas R. Accelerated Cellular Senescence in Progressive Multiple Sclerosis: A Histopathological Study. Ann Neurol. 2025 Feb 1. doi: 10.1002/ana.27195. Epub ahead of print.
• Katsarou A, Tzikopoulou M, Papadopoulos D, Palioura S, Falagas ME. Optic and peripheral neuropathy associated with short and prolonged administration of tedizolid: a review. Expert Rev Anti Infect Ther. 2025 Jan;23(1):49-65. doi: 10.1080/14787210.2024.2448143. Epub 2025 Jan 7.
• Chatzidakis S, Bakiri ZM, Faropoulos K, Fotakopoulos G, Georgakopoulou VE, Trakas N, Sklapani P, Spandidos DA, Yiallouris A, Papadopoulos D. Comparison of surgical techniques for the treatment of chronic subdural hematomas: A single‑center case series. Exp Ther Med. 2024 Jun 20;28(2):329. doi:10.3892/etm.2024.12618.
• Oz A, Tsoumas I, Lampropoulos K, Xanthos T, Karpettas N, Papadopoulos D. Cardiac Rehabilitation After TAVI -A Systematic Review and Meta-Analysis. Curr Probl Cardiol. 2023 Mar;48(3):101531. doi: 10.1016/j.cpcardiol.2022.101531. Epub 2022 Dec 7.
• Choi S, Hill D, Guo L, Nicholas R, Papadopoulos D, Cordeiro MF. Automated characterisation of microglia in ageing mice using image processing and supervised machine learning algorithms. Sci Rep. 2022 Feb 2;12(1):1806. doi: 10.1038/s41598-022-05815-6.
  
• Papadopoulos D, Gklinos P, Psarros G, Drellia K, Delicha EM, Friede T, Mitsikostas DD, Nicholas RS. Disease-modifying treatments for multiple sclerosis have not affected the incidence of neoplasms in clinical trials over 3 decades: a meta-analysis with meta-regression. J Neurol. 2022 Jun;269(6):3226-3237. doi: 10.1007/s00415-021-10932-9. Epub 2022 Jan 23.
• Stanulović V, Hodolic M, Mitsikostas DD, Papadopoulos D. Drug tolerability: How much ambiguity can be tolerated? A systematic review of the assessment of tolerability in clinical studies. Br J Clin Pharmacol. 2022 Feb;88(2):551-565. doi: 10.1111/bcp.15016. Epub 2021 Aug 31.
• Drellia K, Kokoti L, Deligianni CI, Papadopoulos D, Mitsikostas DD. Anti-CGRP monoclonal antibodies for migraine prevention: A systematic review and likelihood to help or harm analysis. Cephalalgia. 2021 Jun;41(7):851-864. doi: 10.1177/0333102421989601.
• Gklinos P, Papadopoulou M, Stanulovic V, Mitsikostas DD, Papadopoulos D. Monoclonal Antibodies as Neurological Therapeutics. Pharmaceuticals (Basel). 2021 Jan 26;14(2):92. doi: 10.3390/ph14020092.
• Mitsikostas DD, Doskas T, Gkatzonis S, Fakas N, Maltezou M, Papadopoulos D, Gourgioti R, Mitsias P. A Prospective, Observational, Cohort Study to Assess the Efficacy and Safety of Prolonged-Release Fampridine in Cognition, Fatigue, Depression, and Quality of Life in Multiple Sclerosis Patients: The FAMILY Study. Adv Ther. 2021 Mar;38(3):1536-1551. doi: 10.1007/s12325-020-01606-5. Epub2021 Feb 2.
• Koutsoudaki PN, Papadopoulos D, Passias PG, Koutsoudaki P, Gorgoulis VG. Cellular senescence and failure of myelin repair in multiple sclerosis. Mech Ageing Dev. 2020 Dec;192:111366. doi: 10.1016/j.mad.2020.111366. Epub 2020 Sep28.
• Papadopoulos D, Magliozzi R, Mitsikostas DD, Gorgoulis VG, Nicholas RS. Aging, Cellular Senescence, and Progressive Multiple Sclerosis. Front Cell Neurosci. 2020 Jun 30;14:178. doi: 10.3389/fncel.2020.00178.
• Kokoti L, Drellia K, Papadopoulos D, Mitsikostas DD. Placebo and nocebo phenomena in anti- CGRP monoclonal antibody trials for migraine prevention: a meta-analysis. J Neurol. 2020 Apr;267(4):1158-1170. doi: 10.1007/s00415-019-09673-7. Epub 2020 Jan 9.
• Gklinos P, Papadopoulos D, Mitsikostas DD. Nocebo in multiple sclerosis trials: A meta-analysis on oral and newer injectable disease-modifying treatments. Mult Scler Relat Disord. 2019 Nov;36:101389. doi: 10.1016/j.msard.2019.101389. Epub 2019 Sep 9.
• Papadopoulos D, Mitsikostas DD. Authors' Reply to Tsivgoulis et al.: "Oral Disease-Modifying Treatments for Relapsing Multiple Sclerosis: A likelihood to Achieve No Evidence of Disease Activity or Harm Analysis". CNS Drugs. 2019 Mar;33(3):297-298. doi: 10.1007/s40263-019-00616-4.
• Papadopoulos D, Mitsikostas DD. Correction to: Oral Disease-Modifying Treatments for Relapsing Multiple Sclerosis: A Likelihood to Achieve No Evidence of Disease Activity or Harm Analysis. CNS Drugs. 2019 Jan;33(1):93-97. doi: 10.1007/s40263-018-0595-4. Erratum for: CNS Drugs. 2018 Nov;32(11):1069-1078. doi: 10.1007/s40263-018-0547-z.
• Kritsilis M, V Rizou S, Koutsoudaki PN, Evangelou K, Gorgoulis VG, Papadopoulos D. Ageing, Cellular Senescence and Neurodegenerative Disease. Int J Mol Sci. 2018 Sep 27;19(10):2937. doi: 10.3390/ijms19102937.
• Papadopoulos D, Mitsikostas DD. Oral Disease-Modifying Treatments for Relapsing Multiple Sclerosis: A Likelihood to Achieve No Evidence of Disease Activity or Harm Analysis. CNS Drugs. 2018 Nov;32(11):1069-1078. doi: 10.1007/s40263-018-0547-z. Erratum in: CNS Drugs. 2019 Jan;33(1):93-97. doi: 10.1007/s40263-018-0595-4.
• Mitsikostas DD, Mastorodemos V, Tsagournizakis M, Kodounis A, Tsagkaropoulos A, Konitsiotis S, Toulas P, Papadimitriou A, Papadimitriou D, Tavernarakis A, Papadopoulos D. Natalizumab-related progressive multifocal leukoencephalopathy in Greece. Mult Scler Relat Disord. 2014 Mar;3(2):203-10. doi: 10.1016/j.msard.2013.08.006. Epub 2013 Sep 24.
• Kontogeorgi E, Papadopoulos D, Zafeiropoulou E, Karagkounis G, Argyrakos T, Stranjalis G, Rontogianni D, Karakalos D. A 24 year-old woman with relapsing brainstem manifestations and multiple focal brain lesions. Natural killer cell lymphoblastic lymphoma/leukemia. Brain Pathol. 2015 Jan;25(1):115-6. doi: 10.1111/bpa.12235.
• Karapanou O, Vlassopoulou B, Tzanela M, Papadopoulos D, Angelidakis P, Michelakakis H, Ioannidis G, Mihalatos M, Kamakari S, Tsagarakis S. X-linked adrenoleukodystrophy: are signs of hypogonadism always due to testicular failure? Hormones (Athens). 2014 Jan-Mar;13(1):146-52. doi: 10.1007/BF03401330.
• Tsakiri N, Papadopoulos D, Denis MC, Mitsikostas DD, Kollias G. TNFR2 on non-haematopoietic cells is required for Foxp3+ Treg-cell function and disease suppression in EAE. Eur J Immunol. 2012 Feb;42(2):403-12. doi: 10.1002/eji.201141659. Epub 2011 Dec 16.
• Papadopoulos D, Mitsikostas DD. A meta-analytic approach to estimating nocebo effects in neuropathic pain trials. J Neurol. 2012 Mar;259(3):436-47. doi: 10.1007/s00415-011-6197-4. Epub 2011 Aug 3.
• Mitsikostas DD, Viskos A, Papadopoulos D. Sleep and headache: the clinical relationship. Headache. 2010 Jul;50(7):1233-45. doi: 10.1111/j.1526-4610.2010.01729.x.
• Papadopoulos D, Mitsikostas DD. Nocebo effects in multiple sclerosis trials: a meta-analysis. Mult Scler. 2010 Jul;16(7):816-28. doi: 10.1177/1352458510370793. Epub 2010 Jun 10. PMID: 20538704.
• Papadopoulos D, Rundle J, Patel R, Marshall I, Stretton J, Eaton R, Richardson JC, Gonzalez MI, Philpott KL, Reynolds R. FTY720 ameliorates MOG- induced experimental autoimmune encephalomyelitis by suppressing both cellular and humoral immune responses. J Neurosci Res. 2010 Feb 1;88(2):346-59. doi: 10.1002/jnr.22196. PMID: 19658199.
• Papadopoulos D, Dukes S, Patel R, Nicholas R, Vora A, Reynolds R. Substantial archaeocortical atrophy and neuronal loss in multiple sclerosis. Brain Pathol. 2009 Apr;19(2):238-53. doi: 10.1111/j.1750-3639.2008.00177.x. Epub 2008 May 20.
• Papadopoulos D, Ewans L, Pham-Dinh D, Knott J, Reynolds R. Upregulation of alpha-synuclein in neurons and glia in inflammatory demyelinating disease. Mol Cell Neuroschi. 2006 Apr;31(4):597-612. doi: 10.1016/j.mcn.2006.01.007. Epub 2006 Feb 28.
• Papadopoulos D, Pham-Dinh D, Reynolds R. Axon loss is responsible for chronic neurological deficit following inflammatory demyelination in the rat. Exp Neurol. 2006 Feb;197(2):373-85. doi: 10.1016/j.expneurol.2005.10.033. Epub 2005 Dec 9.
• Reynolds R, Dawson M, Papadopoulos D, Polito A, Di Bello IC, Pham-Dinh D, Levine J. The response of NG2-expressing oligodendrocyte progenitors to demyelination in MOG-EAE and MS. J Neurocytol. 2002 Jul-Aug;31(6-7):523-36. doi: 10.1023/a:1025747832215.

Published abstracts of talks at international conferences

1. Papadopoulos D, Karamita M, Mitsikostas DD, Gorgoulis V, Probert L, Nicholas. Accelerated cellular senescence in a model of multiple sclerosis (S50. 004).In session: “MS Novel Therapeutics and Animal Models”. 69th Annual Meeting of the American Academy of Neurology, 28 Απριλίου 2017, Bοστώνη, ΗΠΑ.
2. Mitsikostas DD, Papadopoulos D, Mantonakis LI, Chalarakis NG, Stathis P, Smpiliris M, Delicha E, Sfikakis PP. Nocebo in Neurology: A meta-analysis with important implications for clinical practice and trial design. (S38. 005). 64th Annual Meeting of the American Academy of Neurology, 2012, Νέα Ορλεάνη, ΗΠΑ
3. Tsakiri N, Papadopoulos D, Denis M, Mitsikostas D, Kollias G. TNFR2-expressing non-haematopoetic cells modulate the immunosuppressive activity of FoxP3+ regulatory T cells in MOG-EAE. (S47). In session: “Cell-based therapies in MS” 5th Joint Triennial Congress of ECTRIMS-ACTRIMS, 21 Οκτωβρίου 2011, Άμστερνταμ, Ολλανδία
4. Dukes S, Papadopoulos D, Patel R, Nicholas R, Vora A, Reynolds R. (2008). Extensive de- afferentation in the hippocampus in multiple sclerosis. (S: 183). 9th European Congress of Neuropathology, 8 Μαΐου, 2008, Αθήνα.
5. Dukes S, Patel R, Papadopoulos D, Vora A, Nicholas R, Reynolds R (2007). Archaeocortical lesions in multiple sclerosis: a quantitative histopathological study. (S339). Annual meeting of the Association of British Neurologists Scientific Meeting, 14-16 Νοεμβρίου 2007, Λονδίνο, Ηνωμένο Βασίλειο.
6. Papadopoulos D & Reynolds R. Axonal loss is the pathological correlate of chronic disability in the Myelin Oligodendrocyte Glycoprotein-induced EAE model of Multiple Sclerosis. 103rd Meeting of the British Neuropathological Society held jointly with the French Society for Neuropathology, 18 Δεκεμβρίου 2002, Σαουθάμπτον, Ηνωμένο Βασίλειο.
7. Abedin KJ, Papadopoulos D, Dexter DT, Reynolds R. Oxidative DNA damage in the spinal cord in Multiple Sclerosis. 103rd Meeting of the British Neuropathological Society held jointly with the French Society for Neuropathology, 18 Δεκεμβρίου 2002, Σαουθάμπτον, Ηνωμένο Βασίλειο.
8. Patani R, Balaratnam M, Papadopoulos D, Polito A, Reynolds R. Extensive sampling is required to reveal the true degree of remyelination in multiple sclerosis. 103rd Meeting of the British Neuropathological Society held jointly with the French Society for Neuropathology, 18 Δεκεμβρίου 2002, Σαουθάμπτον, Ηνωμένο Βασίλειο.
9. Papadopoulos D & Reynolds R. Axonal damage in myelin/oligodendrocyte glycoprotein induced EAE in the rat. Στο workshop: “ ΕΑΕ: Immune mechanisms”. 6th International Congress of the International Society of Neuroimmunology, 4 Σεπτεμβρίου 2001, Εδιμβούργο, Σκωτία.

Published abstracts of announcements at international conferences

1. Palli N, Papadopoulos D, Tsioutis C, Angouridis A. (2024). High-density lipoprotein cholesterol and multiple sclerosis: A systematic review and meta-analysis. Atherosclerosis. Vol 395 Suppl 1; 117807
2. Papadopoulos D, Magliozzi R, Bandiera S, Cimignolo I, Barusolo E, Probert L, Reynolds R, Nicholas R. (2022). Accelerated cellular senescence in progressive multiple sclerosis. MULTIPLE SCLEROSIS JOURNAL 28 (3_ SUPPL), 498-499
3. Choi S, Nicholas R, Papadopoulos D, Cordeiro MF. (2023). Characteristics of retinal ganglion cell (RGC) degeneration with age and cuprizone-induced model of multiple sclerosis (CPZ-MS). Investigative Ophthalmology & Visual Science 64 (8), 5462-5462
4. Choi S, Hill D, Guo L, Luong V, Papadopoulos D, Nicholas R, Cordeiro MF. (2021). Automated Characterisation of Retinal Microglia in a Multiple Sclerosis Mouse Model and Age-Matched Controls Investigative Ophthalmology & Visual Science 62 (8), 1682-1682
5. Papazian I, Avloniti M, Karamita, M, Nicholas R, Probert L; Papadopoulos D. (2021). Chronic demyelination-induced cell senescence is responsible for motor impairment in a model of MS. MULTIPLE SCLEROSIS JOURNAL; 27: 2-SUPPL: 381-381
6. Nicholas, R, Bandiera, S, Magliozzi R, Reynolds R, Papadopoulos D. (2020). Demyelinated White Matter Exhibits Upregulated DNA Damage Response and Cellular Senescence in Progressive Multiple Sclerosis. Annual Meeting of the American-Academy-of-Neurology NEUROLOGY 94 (15)
7. Gklinos P, Papadopoulos D, Mitsikostas D (2019). Nocebo in multiple sclerosis trials: a meta-analysis on oral and newer injectable disease-modifying treatments. Mult SclerJ 25 (S2): 522.
8. Kokoti L, Drelia K, Papadopoulos D, Mitsikostas DD (2019). A15 Placebo And Nocebo Responses In Anti-CGRP Monoclonal Antibody Trials For Migraine Prevention: a meta-analysis. The Journal of Headache and Pain 2019, 20(Suppl 1):109.
9. Karamita M, Nicholas R, Papazian E, Avlonitou M, Mitsikostas D, Probert L, Papadopoulos D (2018). P427: Age and chronicity of demyelination determine motor impairment in a model of multiple sclerosis. Mult SclerJ 24 (S2): 181-182.
10. Karamita M, Nicholas R, Kokoti L, Rizou S, Mitsikostas DD, Gorgoulis V, Probert L, Papadopoulos D (2018). Cellular Senescence Correlates with Demyelination, Brain Atrophy and Motor Impairment in a Model of Multiple Sclerosis (P2.405). Neurology 90 (15 Supplement), P2. 405
11. Mitsikostas DD, Papadopoulos D (2018). Comparing Benefit-Risk Profiles of Oral DMTs for Relapsing MS: A Likelihood of Help vs. Harm (LHH) Analysis.(P4. 388). Neurology 90 (15 Supplement), P4. 388
12. Karamita M, Papadopoulos D, Mitsikostas DD, Gorgoulis V, Probert L, Nicholas R (2017). Axonal damage and motor impairment correlate with glial cell senescence in a model of multiple sclerosis. Mult SclerJ 23, 790-791.
13. Papadopoulos D, Karamita M, Mitsikostas DD, Gorgoulis V, Probert L, Nicholas R (2017). Accelerated cellular senescence in a model of multiple sclerosis (S50. 004) Neurology 88 (16 Supplement), S50. 004
14. Papadopoulos D, Antoniou N, Tsimaratou K, Mitsikostas DD, Gorgoulis V, Nicholas R (2014). A quantitative histopathological study of the effects of arsenic oxides on inflammation, demyelination and neurodegeneration in multiple sclerosis: Pp4150. Eur J Neurol 21, 677
15. Papadopoulos D, Antoniou N, Tsimaratou K, Gorgoulis V, Mitsikostas DD, Nicholas R (2014). Arsenicals May Prevent Axonal Loss in Multiple Sclerosis: A Histopathological Study (P1. 209). Neurology 82 (10 Supplement), P1. 209
16. Tsatsou K, Mamali M, Verentzioti A, Michas D, Papadopoulos D, Kravaritis D (2012). Downbeat nystagmus: a case report with anti-GAD antibodies, auto-immune thyroiditis and late onset diabetes. Eur J Neurol 19 (Suppl 1): S752.
17. Karagkounis G, Argyrakos T, Ronne E, Dimitriadis E, Papadopoulos D, Stranjalis G, Rontogianni D. (2012). Primary natural Killer cell lymphoblastic leukemia/lymphoma of the central nervous system. Virchows Archiv 461 (Suppl 1): S12.
18. Mitsikostas D, Papadopoulos D, Mantonakis LI, Chalarakis NG, Sfikakis PP (2012): pp181. nocebo In Chronic Pain Disorders: A Meta-analysis With Implications for Clinical Practice And Trial Design. Pain Practice 12, 50
19. Papadopoulos D, Plafadeli A, Zafeiropoulou E, Kontogeorgi E, Alexopoulos H, Zisimopoulou V, Verentzioti A, Dalakas MC, Tavernarakis A. (2012) Natalizumab-related PML in multiple sclerosis: a case report. J Neurol 259 (Suppl 1): S109-S110.
20. Mitsikostas DD, Papadopoulos D, Mantonakis LI, Chalarakis NG, Stathis P, Smpiliris M, Delicha E, Sfikakis PP (2012). Nocebo in Neurology: A meta-analysis with important implications for clinical practice and trial design. Neurology 78 (1 Supplement), S38. 005-S38. 005
21. Tsakiri N, Papadopoulos D, Denis M, Mitsikostas D, Kollias G (2011). TNFR2-expressing non-haematopoetic cells modulate the immunosuppressive activity of FoxP3+ regulatory T cells in MOG-EAE. Mult SclerJ 17 (10): S47-S47.
22. Mitsikostas DD, Papadopoulos D (2011). Substantial Nocebo Effect in Clinical Trials for Neuropathic Pain. Neurology 76 (9): A649-A649.
23. Tsakiri N, Papadopoulos D, Mitsikostas DD, Kolias G. (2010). TNFR2 is critical for Treg immunomodulatory activity in a model of MS. Μult Scler 16: S87-S87.
24. Plafadeli A, E. Zafeiropoulou E, Papadopoulos D, Fili M, Kravaritis D, Tavernarakis A. (2010). Reversible cerebral vasoconstriction syndrome: a rare cause of stroke. Cerebrovasc Dis 29 (suppl 2): S90-S90.
25. Papadopoulos D, Mitsikostas DD (2010). Higher incidence of nocebo responses to disease-modifying treatments than symptomatic treatments in multiple sclerosis trials. J Neurol 257(1): S147-S147.
26. Mitsikostas DD, Papadopoulos D (2010). Nocebo Responses in Disease-Modifying and Symptomatic Treatment Trials for Multiple Sclerosis: A Systematic Review. Neurology 74 (9): A542-A542.
27. Papadopoulos D, Mitsikostas DD (2009). Nocebo effect in multiple sclerosis trials. Mult Scler 15: S143-S143.
28. Rundle JL, Papadopoulos D, Patel R, J Richardson, Reynolds R (2008). Effects of the anti VLA-4 small molecule inhibitor BIO5192 on clinical course and pathology in chronic experimental allergic encephalomyelitis Mult SclerJ 4: S89-S89.
29. Dukes S, Papadopoulos D, Patel R, Nicholas R, Vora A, Reynolds R. (2008). Extensive de- afferentation in the hippocampus in multiple sclerosis. Clin Neuropathol 27 (3): S: 183.
30. Dukes SON, Patel R, Papadopoulos D, Vora AJ, Nicholas RS, Reynolds R (2008). Neurodegeneration in the hippocampus in progressive MS. Neuropath Appl Neuropathol 34 (1): S8-8.
31. Dukes SON, Papadopoulos D, Nicholas R, Vora A, Reynolds R (2007). The hippocampus in multiple sclerosis: evidence of atrophy and neuronal loss. Mult SclerJ 13: S141.
32. Dukes S, Patel R, Papadopoulos D, Vora A, Nicholas R, Reynolds R (2007). Archaeocortical lesions in multiple sclerosis: a quantitative histopathological study. J Neurol Neurosurg Psychiatr 79: S339.
33. Papadopoulos D, Reynolds R (2004). Upregulation of alpha-synuclein expression and axonal loss in inflammatory demyelinating disease in the rat. Neuropathology & Applied Neurobiology 30 (2), 203
34. Reynolds R, Papadopoulos D, Ewans L, Karim J, Vora A (2004). A role for α-synuclein in neurodegeneration in multiple sclerosis and in chronic relapsing EAE in the rat. Mult SclerJ 10: S112-S112.
35. Papadopoulos D & Reynolds R. (2003). Axonal loss is the pathological correlate of chronic disability in the Myelin Oligodendrocyte Glycoprotein-induced EAE model of Multiple Sclerosis. Neuropathol Appl Neurobiol. 29 (2): 186.
36. Patani R, Balaratnam M, Papadopoulos D, Polito A, Reynolds R. (2003). Extensive sampling is required to reveal the true degree of remyelination in multiple sclerosis. Neuropathol Appl Neurobiol 29 (2): 186.
37. Reynolds R & Papadopoulos D (2003). Axonal loss and α-synuclein expression in MOG-induced chronic relapsing EAE in the rat. J Neurochem 87:97-97.
38. Patani R, Balaratnam M, Papadopoulos D, Polito A, Reynolds R. (2003). Remyelination can be extensive in multiple sclerosis despite a long disease course. British Neuroscience Association Annual Meeting (BNA) p. 67.
39. Polito A, Papadopoulos D, Dawson M, Levine J, Reynolds R. (2003). The response of NG-2 expressing oligodendrocyte progenitors to demyelination in MOG-EAE and MS. British Neuroscience Association Annual Meeting (BNA) p.67.
40. Papadopoulos D, Reynolds R. (2003). Axonal loss is the pathological correlate of chronic disability in MOG-induced EAE in the rat. British Neuroscience Association Annual Meeting (BNA) S: 70.
41. Abedin KJ, Papadopoulos D, Dexter DT, Reynolds R (2002). Oxidative DNA damage in the spinal cord in Multiple Sclerosis. Neuropathol Appl Neurobiol 28 (2): 168.
42. Papadopoulos D & Reynolds R (2001). Axonal damage in myelin/oligodendrocyte glycoprotein induced EAE in the rat. J Neuroimmunol 118: 39-49.

CONTACT DETAILS

Secretariat: 210-6502894

e-mail: neuroclinic3@metropolitan-general.gr